Daxor Announces Third Quarter Dividend

NEW YORK, NY, Aug 17 (MARKET WIRE) --
Daxor Corporation (NYSE Amex: DXR), a medical instrumentation and
biotechnology company, today announced that the Board of Directors has
voted to declare a dividend of $0.25 per share. The dividend will be paid
to shareholders of record as of Tuesday, August 25, 2009. The dividend
will be paid on Tuesday, September 8, 2009.

This is the second dividend the Company has declared for 2009. The Company
paid a dividend of $0.10 per share on Monday, June 15, 2009.

These payments are in keeping with the declaration of Company management
in 2008 to pay dividends when funds are available.

For the year ended December 31, 2008, the Company paid a total dividend of
$1.50 per share as follows: $0.25 per share on August 26th and November
26th and a special dividend of $1.00 per share on December 30, 2008.

As part of our ongoing research and development efforts, Daxor was
actively engaged in participating in several clinical trials in three
strategic areas: Intensive Critical Care Medicine, Heart
Failure/Hypertension and Dialysis. Of the five current clinical trials,
one has recently been completed, Blood Volume Analysis in treating ICU
Patients - A Prospective, Randomized Outcome Study. The basis of this
study was to investigate if the inclusion of a measured blood volume
analysis from Daxor's BVA-100 would result in (1) a change in treatment;
(2) improved clinical outcomes; and (3) reductions in the cost of care.

Daxor is also coordinating its first multi-center, prospective, blinded
outcome study in heart failure. The TEAM HF (Treatment to Euvolemia by
Assessment and Measured Blood Volume in Heart Failure) will be comprised
of nine (9) medical centers and a total of 300 patients. This study will
investigate if utilizing a measured blood volume while treating heart
failure patients following a hospital stay will decrease a patient's need
to revisit the hospital, decrease the mortality rate and improve their
overall treatment and quality of life while living with heart failure.

Daxor Corporation manufactures and markets the BVA-100, the only
FDA-approved semi-automated Blood Volume Analyzer. The BVA-100 is used in
conjunction with Volumex, Daxor's single use diagnostic kit. For more
information regarding Daxor Corporation's Blood Volume Analyzer BVA-100,
visit Daxor's website www.Daxor.com.

Contact Information:
Stephen Feldschuh
Chief Operating Officer
212-330-8515
stephen@daxor.com

Diane Meegan
Investor Relations
212-330-8512
dmeegan@daxor.com

Copyright 2009, Market Wire, All rights reserved.

-0-